Dougherty assists in funding sales and marketing, corporate purposes
By Devika Patel
Knoxville, Tenn., June 29 - Urologix, Inc. said it priced a $3.9 million public sale of stock with a $585,000 greenshoe. The deal was announced May 25.
The company will sell 5.2 million common shares at $0.75 apiece. The price per share is a 17.58% discount to the June 28 closing share price of $0.91.
Dougherty & Co. LLC is the underwriter.
Settlement is expected July 5.
Proceeds will be used for sales and marketing initiatives, payments related to the company's license of the Prostiva RF Therapy System technology, research and development activities, working capital and general corporate purposes.
Urologix, based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders.
| Issuer: | Urologix, Inc.
|
| Issue: | Common shares
|
| Amount: | $3.9 million
|
| Greenshoe: | $585,000
|
| Shares: | 5.2 million
|
| Price: | $0.75
|
| Warrants: | No
|
| Underwriter: | Dougherty & Co. LLC
|
| Announcement date: | May 25
|
| Pricing date: | June 29
|
| Settlement date: | July 5
|
| Stock symbol: | Nasdaq: ULGX
|
| Stock price: | $0.91 at close June 28
|
| Market capitalization: | $11.69 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
